Eli Lilly (NYSE:LLY) is reported to be in advanced discussions to acquire psychedelic drug developer AtaiBeckley, according to a Bloomberg News article dated 16 July 2026 that cited people familiar with the matter. The Indianapolis‑based target has seen its market value rise to roughly $2 billion after its share price more than doubled over the past year, and Lilly is said to be negotiating the transaction at a premium to that valuation. The potential acquisition could be announced as early as the current week.
The transaction would broaden Lilly’s neuroscience franchise, complementing its existing blockbuster obesity and diabetes medicines, and reflects the company’s ongoing interest in psychedelic‑based therapies. AtaiBeckley is focused on treatments for treatment‑resistant depression and social anxiety disorder. Its lead asset, BPL‑003, is a fast‑acting psychedelic nasal spray that has delivered encouraging mid‑stage trial results and has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. The growing commercial success of Johnson & Johnson’s Spravato and improving clinical data have heightened industry interest in psychedelic medicines, providing a strategic backdrop for Lilly’s pursuit.
The report notes that Eli Lilly’s stock rose 0.34% while AtaiBeckley’s shares fell 5.47% on the day of the news release. No specific financial terms, closing dates, or regulatory approvals have been disclosed, and the deal remains subject to customary closing conditions.